Detalhe da pesquisa
1.
Decrease in α-Globin and Increase in the Autophagy-Activating Kinase ULK1 mRNA in Erythroid Precursors from ß-Thalassemia Patients Treated with Sirolimus.
Int J Mol Sci;
24(20)2023 Oct 10.
Artigo
em Inglês
| MEDLINE
| ID: mdl-37894732
2.
Thalassaemia is paradoxically associated with a reduced risk of in-hospital complications and mortality in COVID-19: Data from an international registry.
J Cell Mol Med;
26(9): 2520-2528, 2022 05.
Artigo
em Inglês
| MEDLINE
| ID: mdl-35355397
3.
Efficacy and Safety of Teriparatide in Beta-Thalassemia Major Associated Osteoporosis: A Real-Life Experience.
Calcif Tissue Int;
111(1): 56-65, 2022 07.
Artigo
em Inglês
| MEDLINE
| ID: mdl-35243531
4.
Impact of the preparation method of red cell concentrates on transfusion indices in thalassemia patients: A randomized crossover clinical trial.
Transfusion;
61(6): 1729-1739, 2021 06.
Artigo
em Inglês
| MEDLINE
| ID: mdl-33948969
5.
Premature aging of the immune system affects the response to SARS-CoV-2 mRNA vaccine in ß-thalassemia: role of an additional dose.
Blood;
140(15): 1735-1738, 2022 10 13.
Artigo
em Inglês
| MEDLINE
| ID: mdl-36004936
6.
Italian patients with hemoglobinopathies exhibit a 5-fold increase in age-standardized lethality due to SARS-CoV-2 infection.
Am J Hematol;
97(2): E75-E78, 2022 02 01.
Artigo
em Inglês
| MEDLINE
| ID: mdl-34861054
7.
Outcomes in patients with chronic lymphocytic leukemia and TP53 aberration who received first-line ibrutinib: a nationwide registry study from the Italian Medicines Agency.
Blood Cancer J;
13(1): 99, 2023 06 28.
Artigo
em Inglês
| MEDLINE
| ID: mdl-37380630
8.
Expression of γ-globin genes in ß-thalassemia patients treated with sirolimus: results from a pilot clinical trial (Sirthalaclin).
Ther Adv Hematol;
13: 20406207221100648, 2022.
Artigo
em Inglês
| MEDLINE
| ID: mdl-35755297
9.
Dual-energy X-ray absorptiometry pitfalls in Thalassemia Major.
Endocrine;
65(3): 469-482, 2019 09.
Artigo
em Inglês
| MEDLINE
| ID: mdl-31300960
10.
Spermatozoal DNA damage in patients with B thalassaemia syndromes.
Pediatr Endocrinol Rev;
6 Suppl 1: 185-9, 2008 Oct.
Artigo
em Inglês
| MEDLINE
| ID: mdl-19337176
11.
Impact of long-term iron chelation therapy on growth and endocrine functions in thalassaemia.
J Pediatr Endocrinol Metab;
19(4): 471-80, 2006 Apr.
Artigo
em Inglês
| MEDLINE
| ID: mdl-16759032
12.
Chelation therapy and bone metabolism markers in thalassemia major.
J Pediatr Endocrinol Metab;
19(11): 1335-42, 2006 Nov.
Artigo
em Inglês
| MEDLINE
| ID: mdl-17220062
13.
Left ventricular remodeling, systolic function, and diastolic function in young adults with beta-thalassemia intermedia: a Doppler echocardiography study.
Chest;
121(2): 506-12, 2002 Feb.
Artigo
em Inglês
| MEDLINE
| ID: mdl-11834665
14.
Paraplegia due to spinal cord compression by extramedullary erythropoietic tissue in a thalassaemia intermedia patient with gynecomastia secondary to cirrhosis: successful treatment with hydroxyurea.
Pediatr Endocrinol Rev;
2 Suppl 2: 316-8, 2004 Dec.
Artigo
em Inglês
| MEDLINE
| ID: mdl-16462720
15.
Healing of leg ulcers with hydroxyurea in thalassaemia intermedia patients with associated endocrine complications.
Pediatr Endocrinol Rev;
2 Suppl 2: 319-22, 2004 Dec.
Artigo
em Inglês
| MEDLINE
| ID: mdl-16462721
16.
Diabetes mellitus and impaired glucose tolerance in thalassaemia major: incidence, prevalence, risk factors and survival in patients followed in the Ferrara Center.
Pediatr Endocrinol Rev;
2 Suppl 2: 285-91, 2004 Dec.
Artigo
em Inglês
| MEDLINE
| ID: mdl-16462713
17.
HCV and HGV infection, iron overload and liver disease in multitransfused patients with thalassaemia and persistently normal or abnormal transaminase levels.
Pediatr Endocrinol Rev;
2 Suppl 2: 259-66, 2004 Dec.
Artigo
em Inglês
| MEDLINE
| ID: mdl-16462707